IFNB1 and myeloid sarcoma: A proportion of MS patients receiving IFNβ treatment develop neutralizing anti-drug antibodies (NAbs), which at high titers block the biological response [4], [5] and the therapeutic efficacy [6]–[8] of IFNβ.